
    
      The MEDI8852 phase 2a study will evaluate the safety and tolerability of a single intravenous
      (IV) dose of MEDI8852 administered in conjunction with oseltamivir, the safety and
      tolerability of oseltamivir alone and the safety and tolerability of a single IV dose of
      MEDI8852 alone in adult participants with confirmed acute, uncomplicated influenza caused by
      Type A strains. Enrollment is planned in the United States, South Africa, and Australia.
    
  